What can we expect in the financial markets in 2026!
A bullish market response followed the announcement of Neuralink's human trial approval, with shares privately marketed at a $7 billion valuation. These transactions involve early backers and employees, and are not a direct reflection of the company's market value. Neuralink, which raised $205 million at a $2 billion valuation in its last known fundraising in 2021, has been trading shares mostly with smaller investors.
Feel free to send us any request. Our support team is available 5 days a week.
+357 25 010426 (Mon–Fri 8:30–17:00)
We will contact you shortly.
Risk Warning: CFDs are complex instruments and come with a high risk of rapid financial loss due to leverage. 78.70% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.